Vaccinia virus (VV) has been utilized in oncolytic virotherapy, but it risks a host antiviral immune response. VV has an extracellular enveloped virus (EEV) form consisting of a normal virion covered with a host-derived outer membrane that enables its spread via circulation while evading host immune mechanisms. However, the immune resistance of EEV is only partial, owing to expression of the surface protein B5R, which has four short consensus repeat (SCR) domains that are targeted by host immune factors. To engineer a more effective virus for oncolytic virotherapy, we developed an enhanced immune-evading oncolytic VV by removing the SCRs from the attenuated strain LC16mO. Although deletion of only the SCRs preserved viral replication, progeny production, and oncolytic activity, deletion of whole B5R led to attenuation of the virus. Importantly, SCR-deleted EEV had higher neutralization resistance than did B5R-wild-type EEV against VVimmunized animal serum; moreover, it retained oncolytic function, thereby prolonging the survival of tumor-bearing mice treated with anti-VV antibody. These results demonstrate that partial SCR deletion increases neutralization escape without affecting the oncolytic potency of VV, making it useful for the treatment of tumors under the anti-virus antibody existence.
INTRODUCTION
Oncolytic virotherapy is a novel anti-cancer strategy that has shown promising clinical results in the U.S. Food and Drug Administrationapproved talimogene laherparepvec. Several viruses have been engineered as next-generation oncolytic agents with their functionalities enhanced via viral recombination, [1] [2] [3] loading of therapeutic factors, 4 or combination with conventional therapies. 4, 5 However, oncolytic viruses elicit antiviral immune responses in the host that significantly limit their therapeutic potential, especially in reaching remote tumors. [6] [7] [8] Vaccinia virus (VV) can escape antiviral immunity using a unique infectious form-namely, the extracellular enveloped virus (EEV). 9 Most progeny virions mature as the normal infectious form, intracellular mature virus (IMV), and are released after host cell death; however, a few are covered with or wrapped in early endosomes or a trans-Golgi network, yielding an intracellular enveloped virus (IEV) that is exposed on the cell surface (referred to as a cell-associated virus) via membrane fusion before being released as an EEV through actin polymerization. 9 EEVs are far less abundant than IMVs, representing <1% of total infectious virions; 10 however, they have advantages in viral dissemination, such as rapid spreading without causing host cell death 9, 11 and efficient entry into target cells independent of cell-signaling mechanisms. 12, 13 In addition, the EEV outer membrane presents host-derived antigens, such as complement control proteins (e.g., cluster of differentiation [CD]46, CD55, and CD59) and major histocompatibility complex class I, 14, 15 which allow the virus to spread systemically via circulation while escaping neutralization by complement factors or anti-VV antibodies. 15, 16 Some engineered VV strains produce large amounts of EEV (e.g., International Health Department (IHD)-J, vA34R, or WI) due to a point mutation in glycoprotein A34R, 17 making them suitable for oncolytic virotherapy. 2, 3 However, EEV has only partial immune resistance, although it is higher than that of IMV. Of the five EEV outer membrane surface antigens (A33R, A34R, A36R, A56R, and B5R), B5R is the most frequent target of host-neutralizing antibodies. 18, 19 B5R is a 42-kDa envelope glycoprotein containing four short consensus repeat (SCR) domains, whose expression is critical for viral morphogenesis, trafficking, dissemination, and EEV production. [20] [21] [22] [23] [24] [25] However, anti-B5R antibody recognizing the SCR1/SCR2 boundary and/or the B5R stalk region 26 induces complement-dependent EEV neutralization. [27] [28] [29] Whole B5R deletion drastically reduces viral plaque size, pathogenicity, actin polymerization, and EEV production. 21, 24, 25, 30 In contrast, partial SCR deletion causes a variety of viral phenotypes, including a mild reduction in plaque size 22 and comet-shaped spreading similar to that seen in IHD-J. 18, 22, 23, 31 Interestingly, SCR deletion reportedly increases EEV production in rabbit kidney RK13 cells, 22, 23 despite the loss of actin polymerization. [22] [23] [24] 31 Since SCR domains are responsible for EEV neutralization, their deletion may allow the virus to evade anti-B5R antibody 18 without affecting its capacity for replication or oncolytic activity.
To examine the above possibility, we reinforced an immune-evasive form of oncolytic VV by partially deleting the SCRs. This DSCR virus was structured from the low-neurovirulent LC16mO strain isolated from the Lister strain through repeated passaging and selection for temperature sensitivity. 32, 33 Tumor specificity was conferred by limiting viral replication in normal cells via deletion of the two viral mitogen-activated protein kinase-dependent growth factors VV growth factor (VGF) and O1. 34 The resultant DSCR EEV showed enhanced resistance to anti-VV-neutralizing serum and antibody (Ab) compared to that of VV with intact B5R, while replication, progeny virus production, and oncolytic potency were unaffected. Our re- sults demonstrate that DSCR can be an effective agent for cancer treatment, including in patients with pre-existing neutralizing antibodies.
RESULTS

B5R Deletion Affects Vaccinia Viral Phenotype
The effects of B5R mutation were evaluated using three recombinant VVs, namely, B5R-wildtype (WT) LC16mO, B5R-deleted LC16mO D-DsRed, and SCR-deleted LC16mO DSCR ( Figure 1A ). B5R deletion affected not only viral pathogenicity but also phenotype, including plaque formation and progeny virus production. The reduction in viral plaque size was proportional to the extent of B5R deletion, with LC16mO DSCR generating plaques of an intermediate size between the normal-sized LC16mO plaques and smaller LC16mO D-DsRed plaques ( Figure 1B) . Progeny virus production was markedly reduced by complete deletion of B5R, but not SCR. LC16mO D-DsRed showed decreased EEV and IMV production compared to that of LC16mO ( Figure 1C) ; in contrast, progeny virus production was mostly unaltered for LC16mO DSCR, but EEV production in A549 lung carcinoma cells was increased.
SCR Deletion Alters EEV Generation without Reducing Normal Progeny Virus Production and Oncolytic Activity
Progeny virus production by B5R-WT and SCR-deleted viruses was evaluated in various human cancer cell lines. VGF and O1 were deleted in both viruses to confer tumor-specific viral replication ( Figure 1D) Figure S1A ).
EEV and IMV were recovered from various human cancer cell lines infected with B5R or DSCR at an MOI of 0.1, and they were titrated in RK13 cells. EEV or IMV phenotype was distinguished concisely by detecting host cellular CD46 and viral D8L. Both EEV and IMV expressed the viral D8L protein, but host cellular CD46 was presented only in EEV covered with host-derived membrane ( Figure S1B ). EEV production by B5R and DSCR viruses differed in the various human cancer cell lines (Table 1 ; Figure S2 ); DSCR increased EEV production in all ovarian carcinoma cell lines (A2780, CaOV3, RMG-1, and SKOV3), LoVo colon carcinoma cells, HepG2 hepatocellular carcinoma cells, and A549 cells, but it decreased production in BxPC3 and Panc1 pancreatic cancer cells, HT29 and SW480 colon carcinoma cells, and Hep2 laryngeal carcinoma cells (all p < 0.05). On the other hand, most cell lines showed no differences between IMV production by B5R and DSCR viruses, with only four cell lines showing statistically significant differences.
The oncolytic activity of B5R and DSCR was compared in human ovarian cancer cell lines, which tend to have high EEV production. Cells were separately infected with EEV from culture supernatant or with whole virus including IMV, and cell viability was evaluated. Viral infection area increased in A2780 and CaOV3 cells upon infection with DSCR-derived EEV (Figure 2A) , with a concomitant decrease in viability as compared to cells treated with B5R-derived EEV ( Figure 2B ). There were no differences in infection area or viability between RMG-1 and SKOV3 ovarian carcinoma cells (Figures 2A and 2B ). On the other hand, viral expansion and viability were comparable between B5R and DSCR following whole-virus infection ( Figures 2C and 2D ). These results are consistent with the observed IMV productivity of each virus (Table 1 ; Figure S2B ). 3B ). This suggests that most patients have no pre-existing antibodies against VV (including its EEV form). Therefore, artificially immunized animal serum was used to explore anti-EEV Abs. The ND 50 and ELISA titer were measured in serum derived from cynomolgus monkeys treated with three different doses of VV (high dose = 10 8 plaque-forming units [PFU], low dose = 10 7 PFU, and mock = 0 PFU) (Table S2 ; Figures 3C and 3D ). In immunized serum (non-mock treated), neutralization activity and antibody response against whole VV and B5R increased as a function of viral dose (Table S2 ; Figures 3C and 3D) . Thus, the serum had potential for EEV neutralization.
To compare neutralization resistance, monkey serum samples were mixed with progeny virions from B5R or DSCR, and GFP expression and cytotoxicity of the escaped viruses were evaluated. Half or nearly all B5R EEV was neutralized by 1% high (001) or low (006) VV dose-immunized serum. In contrast, DSCR EEV escaped neutralization at the same concentration of immunized serum ( Figure 4A ). Quantification of GFP fluorescence revealed that DSCR EEV had higher replicative capacity than did B5R EEV, especially when mixed with 0.5% or 1% immunized serum (Figure 4B ). Furthermore, cell viability was inversely proportional to viral GFP expression, and it was lower for DSCR EEV mixed with 0.5% or 1% high or low VV dose-immunized serum than for B5R EEV ( Figure 4C ). In IMV neutralization, B5R and DSCR were inhibited by almost comparable concentrations of immunized serum ( Figure 4D ). These findings are consistent with observed trends for viral replication and oncolytic activity; that is, B5R and DSCR IMVs showed similar variations in GFP expression ( Figure 4E ) and infected cell viability ( Figure 4F ). Thus, SCR deletion affects EEV, but not IMV, and DSCR-derived Various tumor cell lines were infected with B5R or DSCR at an MOI of 0.1. EEVs and IMVs were recovered from the cultures 48 h later, and they were titrated in RK13 cells as described in Figure 1C . The table shows the progeny virus productive ratio of DSCR to B5R. Titers are listed in Figure S2 . *p < 0.05, **p < 0.01, ***p < 0.001 (unpaired t test).
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SCR-Deleted VV Escapes Complement-Dependent EEV Neutralization
EEV is neutralized by anti-B5R antibody combined with complement; [27] [28] [29] we therefore mixed EEV and IMV derived from B5R and DSCR with rabbit anti-VV antibody (immunoglobulin G [IgG] fraction, anti-B5R antibody was detected by ELISA; data not shown) and rabbit complement separately. These mixtures were used to infect SKOV3 cells, and the replication of active virus was observed by fluorescence microscopy. B5R EEV showed slight resistance to anti-virus antibody and complement alone, but it was strongly suppressed by the combination of >0.2% antibody and 3% complement (Figure 5A ). DSCR EEV showed higher immune resistance than did B5R EEV, escaping mixtures of up to 0.5% antibody and 10% complement. Accordingly, DSCR EEV showed higher GFP than B5R expression when mixed with antibody and complement ( Figure 5B ). Similar results were obtained using RMG-1 (Figure S3A) and A2780 (data not shown) cells as EEV-producing and -infecting cells, respectively. DSCR EEV decreased the viability of RMG-1 cells more than did B5R EEV when mixed with antibody and 3%-10% complement ( Figure S3B ).
Neither IMV escaped anti-virus antibody and complement alone or in combination (Figure 5C ). Both B5R and DSCR IMVs were strongly inhibited by >0.2% antibody and/or 3% complement. There was no difference in viral GFP expression between B5R and DSCR IMVs ( Figure 5D ). These results suggest that EEV neutralization depends on the combination of antibody and complement, and SCR-deleted VV efficiently escapes their neutralizing activity.
SCR Deletion Enhances the Oncolytic Activity of EEV in the Presence of Anti-virus Antibody
The neutralization resistance and oncolytic activity of EEVs were examined in a mouse model of anti-VV antibody-induced peritoneal dissemination. Athymic nude mice bearing A2780 ovarian cancer cells were injected with anti-VV antibody (IgG fraction) derived from immunized rabbit or PBS, followed by intraperitoneal injection of B5R or DSCR EEV. Viral replication and tumor growth were evaluated based on firefly luciferase (Fluc) and Renilla luciferase (Rluc) expression, respectively.
Fluc luminescence reflecting viral distribution was reduced by antibody pretreatment on day 3 after virus injection; however, on day 7, DSCR EEV showed higher replication than did B5R EEV in the presence of antibody ( Figure 6A, middle) . On the other hand, the level of Rluc luminescence in tumors, which reflected tumor growth, was similar among mice before virus injection ( Figure 6A , top), but it disappeared on day 8 after injection upon the administration of either B5R or DSCR EEV without antibody pretreatment. In contrast, in the presence of antibody, tumors disappeared in half of DSCR EEV-treated mice, while they only disappeared in a single B5R EEV-treated mouse ( Figure 6A , bottom).
Quantitative analysis of viral Fluc luminescence revealed that the replication kinetics of both EEVs were similar in the absence of antibody ( Figure 6B ). When antibody was present, the peak intensity of viral Fluc signals was delayed 2 days by DSCR EEV and 5 days by B5R EEV ( Figure 6B ). DSCR EEV showed higher replication than did B5R EEV on day 7 after virus injection with antibody pretreatment (p < 0.05). Quantification of tumor Rluc luminescence indicated that the signal in mice without antibody treatment was almost completely abolished by B5R and DSCR EEVs. In contrast, DSCR EEV suppressed tumor signals in antibody-treated mice to levels in mice without antibody treatment, whereas the anti-cancer effect of B5R EEV was strongly inhibited by antibody treatment ( Figure 6C ). The survival of mice was prolonged by injection with B5R and DSCR EEVs without anti-VV antibody treatment as compared to survival after mock treatment ( Figure 6D ). Meanwhile, DSCR EEV prolonged the survival of mice with and without antibody treatment, although antibody treatment reduced survival in B5R EEV-treated mice ( Figure 6D ). The log rank test showed that the B5R EEV-antibody combination prolonged survival compared to that in mice treated with PBS-antibody (p = 0.0041); however, DSCR EEV-antibody had an even greater effect (p = 0.0291). Thus, B5R and DSCR EEVs have comparable therapeutic efficacies in the absence of anti-virus antibody, whereas DSCR EEV is more potent when antibody is present.
DISCUSSION
The balance of antitumor and antiviral immunity is the most important determinant of the efficacy of oncolytic virotherapy; the efficacy is enhanced by the former and inhibited by the latter. Antitumor immunity can be enhanced by several strategies, including the loading of immunotherapeutic agents (e.g., cytokines, chemokines, and co-stimulation molecules) and/or combined immunecheckpoint blockade. 4 Pre-existing antiviral immunity does not necessarily inhibit the viral therapeutic effect, especially in the case of direct intratumoral injection. 35 However, there is evidence that the oncolytic effect of therapeutic viruses is enhanced by immunosuppression. 6, 8, 36 Furthermore, since pre-existing immunity potently inhibits viral delivery to remote organs, 3, [6] [7] [8] virus injection is basically limited to the intratumoral route. Although various strategies have been developed to escape antiviral immunity, such as carrier-cell therapy, 5, 7 lipid coating, 37 and immunosuppression, [6] [7] [8] 36 there are none based on viruses alone.
In this study, we enhanced the ability of an immune-resistant form of VV to escape host antivirus antibody by partially deleting the antigenic SCR region of the viral glycoprotein B5R. Whole-B5R deletion significantly reduced viral plaque size as well as both EEV and IMV production ( Figures 1B and 1C) . SCR-deleted virus (DSCR) had an intermediate plaque size between those of whole-B5R deletion and WT viruses ( Figure 1B) , which is consistent with a previous report. 22 However, SCR deletion had almost no effect on IMV production ( Figure 1C ; Figure S2B ) or oncolytic activity compared to levels after infection by the WT virus (B5R) (Figures 2C and 2D) , and it tended to increase EEV production, especially in ovarian cancer cell lines such as A2780 and CaOV3 (Table 1; Figure S2A ), which showed decreased viability with increasing EEV titer ( Figure 2B ). These symptoms suggest the potential of EEV utilization because of the lower productivity of the WT virus.
The effect of DSCR on EEV production varied among tumor cell types, suggesting the influence of host cell factors on EEV morphogenetic processes, such as viral entry, transport, wrapping, exposure, or egress. In contrast, IMV formation was unaffected, as evidenced by the comparable levels of IMV productivity of B5R and DSCR. B5R regulates several aspects of morphogenesis; however, EEV entry requires an intact B5R stalk region, 38 while mature virion transfer and accumulation in the wrapping region depend on the transmembrane domain and cytoplasmic tail of B5R, respectively, but not on the SCRs. 39 A major function of the SCRs is to mediate switching from microtubule transport to actin-based motility during EEV exposure at the cell surface. 40 SCR4 is the region responsible for this activity, but the DSCR virus maintained or increased EEV productivity in various tumor cell lines (>70% of cells, as shown in Table 1 ). DSCR EEV may readily egress by detaching from the cell surface due to loss of interaction between the luminal domain of B5R and the plasma membrane, similar to SCR4-mutated (B5R P189S ) VV. 41 Thus, cells with high EEV productivity may support viral wrapping and/or transport out of the cell in the case of DSCR.
There are several factors that may facilitate the processes described above. For example, RAB1A-a member of the Ras oncogene family-mediates trafficking of matured virions to the wrapping site. 42 During the wrapping process, VV utilizes retrograde transport factors in the Golgi-associated transport pathway, such as syntaxin 6 and vacuolar protein sorting 52 homolog. 43, 44 In addition, wrapped virions (IEV) employ microtubule transport to reach the cell membrane through recruitment of kinesin-1 by the IEV-associated protein A36R.
45-47
The kinesin-1 component KIF5B is associated with lung cancer prognosis, 48 and other kinesin family members have also been implicated in the progression of various malignancies, including ovarian cancer. [49] [50] [51] Microtubule dynamics are important not only to tumor growth but also to drug resistance, especially to those used to treat ovarian cancers, as these mainly target the tumor cell cytoskeleton. 52, 53 As for preexisting anti-virus antibodies, we explored anti-VV and -B5R (EEV-specific) antibodies from human and immunized monkey serum. Interestingly, there were almost no VV-or B5R-specific antibodies in the vaccinated human serum (Figures 3A and 3B ). This result is consistent with past clinical reports of systemic VV treatment, which resulted in comparable therapeutic effects regardless of base neutralizing titer or vaccination history. 54, 55 This suggests that most patients have few pre-existing antibodies that neutralize the virus sufficiently, likely due to the end of smallpox vaccination in the 1980s.
On the other hand, both anti-VV and -B5R antibodies were clearly detected in immunized monkey serum in proportion to vaccine dosage ( Figures 3C and 3D) . The levels of VV-and B5R-specific antibodies were measured on days 1, 3, 7, 20, and 30 after virus injection, and very high levels of antibody titers were induced after day 20 (data not shown). This was consistent with the previous finding that anti-VV antibodies are elicited in human cancer patients within 1 month after virus treatment. [55] [56] [57] [58] Furthermore, the elicitation of anti-VV antibodies strongly decreases the viral titers in blood following repeated intravenous VV injections in cancer patients. 59 Therefore, immune resistance and oncolytic activity of VV were examined by mixing the viruses with monkey serum. High-and low-VV dose-immunized monkey sera contained anti-B5R antibody ( Figure 3D ) and efficiently neutralized B5R EEV ( Figures 4A and  4B ). On the other hand, DSCR EEV escaped neutralization and retained its oncolytic activity when mixed with either high-or lowdose-immunized serum (Figures 4A-4C) . The former more potently neutralized EEV and IMV than did the latter, according to the recorded ELISA titers against B5R.
EEV neutralization strongly depends on anti-B5R antibody and complement, but SCR deletion enhanced EEV escape upon exposure to those neutralizers ( Figures 5A and 5B) . Rabbit anti-VV antibody (anti-B5R antibody) or complement alone does not neutralize EEV efficiently, but their combination markedly enhanced neutralizing activity against EEV. B5R EEV exhibited greater immune resistance than did B5R IMV ( Figures 5A and 5C ), although some residual antigenicity was neutralized by the antibody-complement combination. However, DSCR EEV showed the greatest resistance ( Figures 5A and 5B), even in the presence of an antibody-complement mixture.
The enhancement of neutralization resistance was confirmed in antivirus antibody-treated mice, in which DSCR EEV promoted viral replication to a greater extent than B5R EEV ( Figure 6B ). Furthermore, DSCR EEV decreased tumor burden and prolonged survival in these mice irrespective of the presence of antibody ( Figures 6C  and 6D ), since a 100 mL volume of anti-virus antibody is equivalent to approximately 0.5% of total murine blood. These data were corroborated by the results of the in vitro neutralization test. This xenograft model used here is artificial, because it utilizes immunodeficient mice and a xenogeneic rabbit anti-VV antibody. This model only simulates the in vitro conditions in the presence of anti-virus antibodies, which cannot be used to examine the immunogenicity of SCR-deleted EEV against the actual vaccinated situation. However, rabbit antibodies (including anti-B5R antibody) exhibit activity of complement-dependent EEV neutralization ( Figures 5A and 5B ) similar to human antibodies. 28 SCR-deleted EEVs escaped neutralization and showed a higher therapeutic effect than did B5R EEV. Therefore, higher antibody resistance and maintenance of oncolytic effect by SCR deletion can be expected in humans with pre-existing anti-VV (anti-B5R) antibodies.
The other EEV-associated protein, A33R, has also been reported to generate EEV-neutralizing antibodies in humans and rabbits. 27 Rabbit anti-VV antibody comprises anti-A33R antibody (manufacture verified). However, SCR-deleted EEV clearly enhanced their antibody resistance through only B5R modification (Figures 5 and 6 ). Anti-B5R antibody is strongly elicited after vaccination in humans, compared with antibodies targeting other EEV-associated antigens (including A33R). 19 As for VV vaccination, B5R protein has a higher protective potential for lethal VV challenge than does A33R. 60 Considering this, EEV neutralization is strongly dependent on B5R-specific antibody. On the other hand, SCR-deleted EEV did not exhibit perfect resistance to antibody and complement, especially when mixed with higher concentrations (Figure 5A ). This might be the result of A33R-specific antibody.
B5R-specific antibody elicitation is strongly reflected in the presence of raised anti-VV antibody titers. 19 Therefore, anti-B5R antibody is a good indicator not only for EEV protection but also for whole-VV vaccination. As for escaping neutralization by oncolytic VVs, the barrier of anti-B5R antibodies will certainly be faced, especially in patients with pre-existing antibodies. This antibody targets two major epitopes of B5R at the SCR1-SCR2 border and stalk. 26 DSCR harbors a deletion in the former region, which confers increased resistance against EEV-neutralizing antibody. The stalk, which is present in DSCR, is important not only for EEV entry 38 but also for the interaction with other EEV membrane proteins, such as A33R and A34R, 61, 62 which are required for B5R incorporation into the EEV outer membrane. Deletion of both the SCR and stalk regions leads to a dramatic reduction in plaque size, comparable to that observed in whole-B5R deletion. 63 Thus, VV with partial SCR deletion (DSCR) shows a good balance between oncolytic activity and immune resistance. This SCR-deleted phenotype was generated in other VV strains, including western reserve (WR) and IHD-J; 18 therefore, it is adaptable for several oncolytic VVs.
In summary, our SCR-deleted virus produced highly neutralizationevasive enveloped virions that retained therapeutic efficacy irrespective of antiviral antibody. VV-specific antibodies are commonly low in patients. However, they are easily elicited after virus inoculation and strongly neutralize the virus, including its EEV form. DSCRderived EEV has potential as a second candidate for treating the patients who have received one or more VV injection, due to its enhanced immune resistance against pre-existing host antibodies. DSCR can also serve as a vector for the delivery of therapeutic agents without interference by the host, and it can potently express loaded agents through stable viral replication. Thus, our SCR-deleted VV is a next-generation platform for oncolytic virotherapy.
MATERIALS AND METHODS
Plasmid Construction
All plasmids used for B5R recombination were generated from the pTN-B5R backbone vector and harbored the B4R, B5R, and B6R gene loci of LC16mO VV. 1 For whole-B5R deletion, the B5R gene in pTN-B5R was replaced with the DsRed gene derived from www.moleculartherapy.org pDsRed-Express-N1 (Takara Bio, Otsu, Japan). The B4R fragment was amplified from pTN-B5R using the primers 5 0 -CAG TCA CGA CGT TGT AAA-3 0 and 5 0 -CAT GCG CAC CTT GAA GCG CAT GAA CTC CTT GAT GAC GTC CTC GGA GGA GGC CAT TTT TAT TTA TGA GCG TTA A-3 0 , and it was digested with NotI and FspI. The DsRed fragment was amplified from pDsRed-Express-N1 with the primers 5 0 -GAG TTC ATG CGC TTC AAG GT-3 0 and 5 0 -CTC AAT TGA TTC TAG CTA TAA GTC TTT AAT CTT TTG ATA CTT GTT CGT TAT TAA TTA TTA ATT ATT TTA ACG GAT TTA TAT CTA CAG GAA CAG GTG GTG-3 0 , and it was digested with FspI and MfeI. The digested PCR fragments were subcloned into the MfeI and NotI sites of pTN-B5R by three-part ligation, yielding pTN-DsRed.
For SCR1-4 deletion, pTN-B5R was digested with NotI and NspI (B4R-B5R signal peptide) or NspI and SacI (B5R stalk-B6R), and the fragments were subcloned into the NotI and SacI sites of pTN-B5R by three-part ligation, yielding pTN-DSCR. The plasmids used for VGF and O1 deletion (pUC19-VGF-ST-lucGFP and pUC19-O1L-ST-BFP) were generated as previously described. carcinoma cell lines were provided by Osaka University (Suita, Japan) and Saitama Medical University (Hidaka, Japan), respectively. The cells were grown in the appropriate medium (Wako, Osaka, Japan) with 10% fetal bovine serum (FBS; Corning, Oneonta, NY, USA)-except for Caco2 (20% FBS) and RK13 (5% FBS) cells-at 37 C in a humidified atmosphere of 5% CO 2 .
Virus Construction
Recombinant viruses were constructed as previously described. 1 Briefly, RK13 cells were infected with LC16mO at an MOI of 0.04, then transfected with pTN-DsRed. Infected cells were harvested 2-5 days later, and recombinant LC16mO D-DsRed virus was selected based on DsRed expression and plaque size reduction, and it was isolated over several cycles of plaque purification. Using LC16mO D-DsRed as the parent virus, recombination was induced in cells transfected with pTN-DSCR to obtain LC16mO DSCR, which was selected based on the loss of DsRed fluorescence and plaque expansion.
VGF-and O1-deleted viruses (LC16mO VGF
À /O1 À ) were generated by insertion of a gene cassette expressing luciferase-fused EGFP and BFP into the VGF and O1 gene loci, respectively. For VGF deletion, RK13 cells were infected with LC16mO and transfected with pUC19-VGF-ST-lucGFP, and LC16mO VGF À was purified as described above and used to infect RK13 cells, which were simultaneously transfected with pUC19-O1L-ST-BFP. LC16mO DSCR VGF À /O1 À was generated by two-step recombination of the B5R gene locus with LC16mO VGF À /O1 À as the parent virus, using pTN-DsRed and pTN-DSCR as described above. All viruses were propagated in A549 cells and titrated in RK13 cells. Viral plaque phenotype was examined and photographed under a phase-contrast or fluorescence microscope (BZ-X700; Keyence, Osaka, Japan) during titration.
EEV and IMV Production
Progeny virus productivity was evaluated by titration. Tumor cell lines were infected with LC16mO, LC16mO D-DsRed, LC16mO
at an MOI of 0.1; 48 h later, the culture medium was collected and centrifuged at 700 Â g for 5 min, and the supernatant was used as the EEV. Infected cells were harvested in 1 mL Opti-MEM (Thermo Fisher Scientific, Waltham, MA, USA), and the cell-associated virions-namely, IMV-were extracted from cell lysates by freeze-thawing, sonication, and centrifugation. Both virions were titrated in RK13 cells, and viral plaques were counted 3-4 days after infection; total PFU was calculated as plaque number relative to fluid volume. C for 1 h, and virus diluents were removed and replaced with the appropriate culture medium. After 48 h, 50 mL medium (including EEV) was recovered from each culture and pipetted onto the newly seeded ovarian cancer cells, which were the same as the EEV-producing cells; 120 h later, cells were photographed under a fluorescence microscope, and viability was assessed with the CellTiter 96 Aqueous Nonradioactive Cell Proliferation Assay (Promega, Madison, WI, USA). Whole viral cytotoxicity was evaluated in cells infected with B5R or DSCR at the same MOI, which were also photographed and assessed for viability 120 h after infection.
Preparation of Serum Sample
Human serum samples were prepared from ovarian cancer patients at Saitama Medical University International Medical Center (Hidaka, Japan). Approval for this project was obtained from the Ethics Committee of Saitama Medical University International Medical Center Whole-virus antigen-and B5R-specific antibody titers in immunized serum were determined by ELISA as previously described. 19, 66 Briefly, Immulon 2HB plates (Thermo Fisher Scientific) were coated with 5 Â 10 6 PFU/well of whole-virus antigen, 660 ng/well of B5R, or PBS (mock). The wells were blocked at 37 C for 2 h with PBS containing 10% FBS, then washed with PBS containing 10% FBS and 0.5% Tween-20. The plates were incubated for 2 h with 4-fold serial dilutions (32Â, 128Â, and 512Â or 4Â, 16Â, 64Â, 256Â, 1,024Â, and 4,096Â) of serum from human patients (221, 183, 195, 175, and 214) or monkeys immunized with high (001, 002, and 003) or low (005, 006, and 008) doses of VV or from mock-immunized monkeys (004, 007, and 009). Rabbit anti-VV serum (IgG fraction; Capricorn Scientific, Ebsdorfergrund, Germany) was used as a positive control in human serum analysis.
After washing, the wells were incubated at 37
C for 1 h with horseradish peroxidase-conjugated rabbit anti-human IgG H&L (diluted 1:4,000; SouthernBiotech, Birmingham, AL, USA), goat anti-monkey IgG H&L (diluted 1:5,000; Abcam, Cambridge, UK), or goat anti-rabbit IgG H&L (diluted 1:4,000; SouthernBiotech). A 100 mL volume of SuperSignal ELISA Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) was added to the washed wells, and optical density at 405 nm (OD 405 ) was recorded with an ARVO MX (PerkinElmer, Waltham, MA, USA). Antibody endpoint titers were defined as the reciprocal of dilutions corresponding to twice the mean OD 405 value of PBS-coated wells.
EEV and IMV Neutralization Assays
EEV and IMV were neutralized by mixing with anti-virus IgG and complement or immunized monkey serum. EEV and IMV were recovered from the supernatant or lysate of SKOV3 cells infected with LC16mO VGF À /O1 À (B5R) or LC16mO DSCR VGF À /O1 À (DSCR) at an MOI of 0.1, as described for EEV or IMV production. In the case of rabbit IgG and complement, about 1,500-2,000 PFU EEV or 5,000-7,000 PFU IMV was mixed with 0%, 0.2%, 0.5%, or 1% rabbit anti-VV immunized serum (IgG fraction; Capricorn Scientific) and 0%, 1%, 3%, 10%, or 25% rabbit complement (Cedarlane Labs, Burlington, ON, Canada), followed by incubation at 37 C for 30 min. The virus-serum-complement mixture was used to infect newly seeded SKOV3 cells, and, after incubation at 37 C for 2 h, the mixture was removed and replaced with the appropriate culture medium. After 96 h, the cells were photographed under a fluorescence microscope, and fluorescence intensity was quantified using the Hybrid Cell Count software (Keyence), according to the manufacturer's protocol.
When RMG-1 cells were used to measure cell viability, about 1,500-5,000 PFU EEV or 6,000-7,000 PFU IMV derived from RMG-1 cells infected with B5R or DSCR was mixed with 0%, 0.2%, or 0.5% rabbit anti-vaccinia IgG and 0%, 1%, 3%, 10%, or 25% complement or with 0%, 0.5%, 1%, 3%, or 5% immunized monkey serum. The mixtures were incubated and used to infect newly seeded RMG-1 cells as described above. After 120 h, cells were photographed, and fluorescence and viability were quantified.
In Vivo Antibody-Treated Mouse Model
To establish an antibody-treated tumor-bearing mouse model, 6-weekold female athymic nude mice (Charles River Laboratories, Yokohama, Japan) were intraperitoneally injected with A2780 cells stably expressing Rluc (5 Â 10 6 cells in 100 mL PBS [pH 7.4]), and they were treated 11 days later (1 day before virus injection) with 100 mL PBS or rabbit anti-VV serum (500 mg/mouse, IgG fraction; Capricorn Scientific) by intraperitoneal injection. Meanwhile, cultured A2780 cells were infected with B5R or DSCR at an MOI 0.05, and, 24 h later, each EEV was recovered from the culture supernatant as described above.
At 12 days after tumor transplantation, the mice were intraperitoneally injected with 500 mL PBS (mock), B5R EEV, or DSCR EEV (6.3 Â 10 4 PFU or 3.5 Â 10 5 PFU, which was determined by titration).
Both antibody and EEVs were treated once. For non-invasive monitoring of tumor growth or viral replication, mice were intraperitoneally injected with 150 mL ViviRen In Vivo Renilla Luciferase Substrate (18.5 mg/mouse; Promega) on days 3, 8, 11, and 15 and with 200 mL VivoGlo Luciferin, In Vivo Grade (3 mg/mouse; Promega) on days 1, 2, 3, 5, 7, and 10 after virus injection. The mice were anesthetized with isoflurane during bioimaging; the bioluminescence of tumor Rluc or viral Fluc was detected by the injection of ViviRen and VivoGlo (Promega), respectively, and it was visualized using NightSHADE LB985 (Berthold Technologies, Bad Wildbad, Germany) and quantified according to the manufacturer's protocol. The experiment was approved by the Animal Experiment Committee of Tottori University.
Statistical Analysis
Differences in progeny virus titers and cell viability among groups were evaluated with the two-tailed unpaired t test, and in vivo bioluminescence was analyzed by two-way ANOVA followed by the Bonferroni test when the ANOVA showed an overall significance. Survival curves were generated with the Kaplan-Meier method and were analyzed with the log rank test. p values <0.05 were considered statistically significant. All statistical analyses were performed using Prism version (v.)5 (GraphPad, La Jolla, CA, USA). 
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